PreveCeutical Medical Inc.
PRVCF
$0.015
-$0.0009-5.66%
| Weiss Ratings | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Weak | |||
| Total Return Index | Fair | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.43 | |||
| Price History | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -14.29% | |||
| 30-Day Total Return | -21.05% | |||
| 60-Day Total Return | -18.03% | |||
| 90-Day Total Return | 20.00% | |||
| Year to Date Total Return | -20.21% | |||
| 1-Year Total Return | -3.85% | |||
| 2-Year Total Return | -21.05% | |||
| 3-Year Total Return | -29.25% | |||
| 5-Year Total Return | 20.00% | |||
| 52-Week High % Change | -39.31% | |||
| 52-Week Low % Change | 59.00% | |||
| Price | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.03 | |||
| 52-Week Low Price | $0.01 | |||
| 52-Week Low Price (Date) | Sep 13, 2024 | |||
| 52-Week High Price (Date) | Feb 05, 2025 | |||
| Valuation | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 9.46M | |||
| Enterprise Value | 12.45M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | 216.67% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -1.85 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | -17.97 | |||
| Enterprise Value/EBIT | -17.79 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 536.94M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | -- | |||
| Address | 5428 Marine Drive West Vancouver, BC V7W 2R2 | |||
| Website | www.preveceutical.com | |||
| Country | Canada | |||
| Year Founded | -- | |||
| Profitability | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -178.01% | |||
| Return on Equity | -- | |||
| Income Statement | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -692.50K | |||
| EBIT (TTM) | -699.80K | |||
| Net Income (TTM) | -996.30K | |||
| Net Income Avl. to Common (TTM) | -996.30K | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -37.77% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | -66.67% | |||
| Balance Sheet | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 200.00 | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 251.20K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -4.65M | |||
| Current Ratio (Q) | 0.051 | |||
| Book Value Per Share (Q) | -$0.01 | |||
| Total Assets (Q) | 336.60K | |||
| Total Current Liabilities (Q) | 4.94M | |||
| Total Debt (Q) | 3.18M | |||
| Total Liabilities (Q) | 4.99M | |||
| Total Common Equity (Q) | -4.65M | |||
| Cash Flow | PRVCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -800.00 | |||
| Cash from Financing (TTM) | 292.80K | |||
| Net Change in Cash (TTM) | -1.10K | |||
| Levered Free Cash Flow (TTM) | -282.50K | |||
| Cash from Operations (TTM) | -291.80K | |||
